Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesca Del Sorbo has a total of 391 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correlations Between Clinical, Anthropometric and Nutritional Evaluations in Patients with Parkinson’s Disease from Ghana: A Cross-Sectional Study

    by Carlotta Bolliri, Luca Magistrelli, Francesca Del Sorbo, Anna Zecchinelli, Daniela Calandrella, Momodou Cham, Elikem Ame-Bruce, Emanuele Cereda, Chiara Pusani, Ioannis Ugo Isaias, et al.

    Introduction: Malnutrition and sarcopenia are commonly observed in African patients with Parkinson’s disease (PD); however, limited data exist regarding the nutritional status and body composition of PD patients in sub-Saharan Africa. This study aims to describe the clinical, nutritional, and anthropometric characteristics of PD patients from Sogakope, in the Volta Region of Ghana. Methods: A total of 20 PD patients were recruited. All participants underwent comprehensive clinical and nutritional assessments. Motor symptoms were evaluated with the Unified Parkinson’s Disease Rating Scale (UPDRS). Dealing with non-motor symptoms, constipation was diagnosed according to the Roma III Criteria while dysphagia was assessed using the Swallowing Disturbance Questionnaire. The presence and impact of sialorrhea was determined using the Sialorrhea Clinical Scale. Nutritional assessment was performed with the Mini Nutritional Assessment short form (MNA-sf). Body composition parameters were measured using Bioelectrical Impedance Analysis (BIA), and muscle strength was evaluated with the Handgrip Strength Test. Correlations were assessed by Pearson or Spearman correlation analysis, as appropriate. Partial correlation analysis controlling for significant clinical variables was also performed. Results: Daily caloric intake was significantly lower compared to Western populations and was associated with a reduced body mass index (BMI) and body fat percentage. Constipation (80%) and sarcopenia (45%) were highly prevalent, whereas dysphagia was reported in only 15% of participants. Over 75% of patients were at risk of malnutrition. A significant inverse correlation was found between thigh circumference and disease duration (r = −0.517; p = 0.02). Additionally, protein intake (g/kg/day) was inversely correlated with motor symptom severity, as measured by the UPDRS Part III in the ON state (r = −0.544; p = 0.02). Conclusions: This study demonstrates a high prevalence of nutritional deficiencies, sarcopenia, and altered body composition in Ghanaian PD patients. These nutritional impairments are significantly associated with disease duration and motor symptom severity. The findings highlight the urgent need for early nutritional screening and intervention as part of a multidisciplinary approach to Parkinson’s disease management in resource-limited settings.

  • Open Access

    B-type natriuretic peptide in Parkinson's disease: a novel biomarker of dysautonomia

    by Elena Contaldi, Marta Corradi, Marco Percetti, Manuela Pilleri, Daniela Calandrella, Ioannis U. Isaias, Gianni Pezzoli, Francesca Del Sorbo


  • Open Access

    Comparing GBA1 ‐Parkinson's disease and idiopathic Parkinson's disease: α‐Synuclein oligomers and synaptic density as biomarkers in the skin biopsy

    by Samanta Mazzetti, Elena Contaldi, Milo Jarno Basellini, Claudia Novello, Alessandra Maria Calogero, Letizia Straniero, Federica Garrì, Valentina Ferri, Daniela Calandrella, Francesca Del Sorbo, et al.

    The main genetic risk factors for Parkinson's disease (PD) are presently represented by variants in GBA1 gene encoding for the β‐glucocerebrosidase (GCase). Searching for a peripheral biomarker that can be used for selecting and monitoring patients in clinical trials targeting GBA1 ‐associated PD ( GBA1 ‐PD) is a current challenge. We previously demonstrated that α‐synuclein oligomers expressed as proximity ligation assay (PLA) score in synaptic terminals of skin biopsy are a reliable biomarker for distinguishing idiopathic PD (iPD) from healthy controls (HC). This cross‐sectional study investigates an unexplored cohort of GBA1 ‐PD ( n = 27) compared to 28 HC, and 36 iPD cases to (i) analyze α‐synuclein oligomers and quantify them throughout PLA score, (ii) investigate GCase expression in brain and synaptic terminals targeting the sweat gland, (iii) unravel indicators that could differentiate patients with specific GBA1 mutations. PLA score discriminates GBA1 ‐PD from HC with sensitivity = 88.9% (95% CI 70.84–97.65), specificity = 88.5% (95% CI 69.85–97.55), and PPV = 88.9% (95% CI 73.24–95.90), AUC value = 0.927 (95% CI 0.859–0.996). No difference was found between GBA1 ‐PD patients and iPD, suggesting a common pathological pathway based on α‐synuclein oligomers. GCase score did not differ in GBA1 ‐PD, iPD, and HC in the synaptic terminals, whereas a positive correlation was found between PLA score and GCase score. Moreover, a significant increase in synaptic density was observed in GBA1 ‐PD compared to iPD and HC ( P < 0.0001). Employing ROC curve to discriminate GBA1 ‐PD from iPD, we found an AUC value for synaptic density = 0.855 (95% CI 0.749–0.961) with sensitivity = 85.2% (95% CI 66.27%–95.81%), specificity = 77.1% (95% CI 59.86%–89.58%), and PPV = 74.19% (60.53%–84.35%). The highest synaptic density values were observed in p.N409S patients. This work points out to the value of both PLA score and synaptic density in distinguishing GBA1 ‐PD from iPD and to their potential to stratify and monitor patients in the context of new pathway‐specific therapeutic options.


  • Open Access

    Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion

    by Federica Garrì, Francesco Paolo Russo, Tommaso Carrer, Luca Weis, Francesca Pistonesi, Michele Mainardi, Michele Sandre, Edoardo Savarino, Fabio Farinati, Francesca Del Sorbo, et al.

  • Negative symptoms in Huntington’s disease

    by Paola Soliveri, Dominga Paridi, Francesca Del Sorbo, Irene Tramacere, Floriano Girotti

    Background Apathy is the commonest psychiatric manifestation in Huntington’s disease (HD). We investigated negative psychiatric symptoms—as determined by the Scale for the Assessment of Negative Psychiatric Symptoms (SANS)—in early and intermediate HD patients, hypothesizing that such symptoms would be prominent and constitute a more comprehensive and clinically relevant assessment than apathy alone. We also assessed relations between negative symptoms and disease stage, mood, motor, and cognitive disturbances. Methods Thirty-five stage 1 and twenty-nine stage 2 consecutive adult HD outpatients were administered SANS; the Scale for the Assessment of Positive Psychiatric Symptoms (SAPS); the motor section of the Unified Huntington’s Disease Rating Scale (UHDRS); Total Functional Capacity (TFC); and instruments to assess cognition, anxiety, and depression. Results The groups had similar age, education, and CAG length. Scores on the Hamilton depression and anxiety scales, and SAPS were similar. Negative symptoms were pervasive in the entire series. Illness duration, UHDRS, TFC, cognition, and SANS scores were significantly worse in stage 2. Mini Mental State Examination (MMSE) and SAPS scores were significantly (multiple regression) associated with SANS score, while Hamilton depression and UHDRS scores were not. SANS score was also associated with stage after removing the cognition-related domains of alogia and attention. Conclusions Negative symptoms are pervasive in HD but more severe in stage 2. The associations of SANS with MMSE and SAPS suggest impaired cognition and thinking as important in generating negative symptoms. SANS appears useful for revealing a wide range of negative symptoms in HD.


  • Clinical correlates of serum 25-hydroxyvitamin D in Parkinson’s disease

    by Michela Barichella, Emanuele Cereda, Laura Iorio, Giovanna Pinelli, Valentina Ferri, Erica Cassani, Carlotta Bolliri, Serena Caronni, Chiara Pusani, Maria Giulia Schiaffino, et al.

    Parkinson’s disease (PD) patients have lower levels of serum 25-hydroxyvitamin D (25(OH)D) than the general population. Previous studies have suggested a negative association between 25(OH)D and cl...


  • Open Access

    Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa

    by Roberto Cilia, Emanuele Cereda, Albert Akpalu, Fred Stephen Sarfo, Momodou Cham, Ruth Laryea, Vida Obese, Kenneth Oppon, Francesca Del Sorbo, Salvatore Bonvegna, et al.

    The natural pattern of progression of Parkinson’s disease is largely unknown because patients are conventionally followed on treatment. As Parkinson’s disease progresses, the true magnitude of the long-duration response to levodopa remains unknown, because it can only be estimated indirectly in treated patients. We aimed to describe the natural course of motor symptoms by assessing the natural OFF in consecutive Parkinson’s disease patients never exposed to treatment (drug-naïve), and to investigate the effects of daily levodopa on the progression of motor disability in the OFF medication state over a 2-year period. In this prospective naturalistic study in sub-Saharan Africa, 30 Parkinson’s disease patients (age at onset 58 ± 14 years, disease duration 7 ± 4 years) began levodopa monotherapy and were prospectively assessed using the Unified Parkinson’s disease Rating Scale (UPDRS). Data were collected at baseline, at 1-year and 2-years follow-up. First-ever levodopa intake induced a significant improvement in motor symptoms (natural OFF versus ON state UPDRS-III 41.9 ± 15.9 versus 26.8 ± 15.1, respectively; P < 0.001). At 1-year follow-up, OFF state UPDRS-III score after overnight withdrawal of levodopa was considerably lower than natural OFF (26.5 ± 14.9; P < 0 .001). This effect was not modified by disease duration. At the 2-year follow-up, motor signs after overnight OFF (30.2 ± 14.2) were still 30% milder than natural OFF (P = 0.001). The ON state UPDRS-III at the first-ever levodopa challenge was similar to the overnight OFF score at 1-year follow-up and the two conditions were correlated (r = 0.72, P < 0.001). Compared to the natural progression of motor disability, levodopa treatment resulted in a 31% lower annual decline in UPDRS-III scores in the OFF state (3.33 versus 2.30 points/year) with a lower model’s variance explained by disease duration (67% versus 36%). Using the equation regressed on pretreatment data, we predicted the natural OFF at 1-year and 2-year follow-up visits and estimated that the magnitude of the long-duration response to levodopa ranged between 60% and 65% of total motor benefit provided by levodopa, independently of disease duration (P = 0.13). Although levodopa therapy was associated with motor fluctuations, overnight OFF disability during levodopa was invariably less severe than the natural course of the disease, independently of disease duration. The same applies to the yearly decline in UPDRS-III scores in the OFF state. Further research is needed to clarify the mechanisms underlying the long-duration response to levodopa in Parkinson’s disease. Understanding the natural course of Parkinson’s disease and the long-duration response to levodopa may help to develop therapeutic strategies increasing its magnitude to improve patient quality of life and to better interpret the outcome of randomized clinical trials on disease-modifying therapies that still rely on the overnight OFF to define Parkinson’s disease progression.


  • Skin Biopsy May Help to Distinguish Multiple System Atrophy–Parkinsonism from Parkinson's Disease With Orthostatic Hypotension

    by Vincenzo Donadio, Alex Incensi, Giovanni Rizzo, Rosa De Micco, Alessandro Tessitore, Grazia Devigili, Francesca Del Sorbo, Salvatore Bonvegna, Rossella Infante, Martina Magnani, et al.

    Background: The differential diagnosis between multiple system atrophy parkinsonism type (MSA‐P) and Parkinson's disease with orthostatic hypotension (PD+OH) is difficult because the 2 diseases have a similar clinical picture. The aim of this study is to distinguish MSA‐P from PD+OH by immunostaining for abnormal phosphorylated α‐synuclein at serine 129 (p‐syn) in cutaneous nerves.Method: We recruited 50 patients with parkinsonism and chronic orthostatic hypotension: 25 patients fulfilled the diagnostic criteria for MSA‐P and 25 patients for PD+OH. The patients underwent a skin biopsy from the cervical area, thigh, and leg to analyze somatic and autonomic skin innervation and p‐syn in skin nerves.Results: Intraneural p‐syn positivity was found in 72% of patients with MSA‐P, mainly in distal skin sites. More important, p‐syn deposits in MSA‐P differed from PD+OH because they were mainly found in somatic fibers of subepidermal plexi, whereas scant autonomic fiber involvement was found in only 3 patients. All patients with PD+OH displayed widely distributed p‐syn deposits in the autonomic skin fibers of proximal and distal skin sites, whereas somatic fibers were affected only slightly in 4 patients with PD+OH. Skin innervation mirrored p‐syn deposits because somatic innervation was mainly reduced in MSA‐P. Sympathetic innervation was damaged in PD+OH but fairly preserved in MSA‐P.Conclusions: The p‐syn in cutaneous nerves allows the differentiation of MSA‐P from PD+OH; MSA‐P mainly shows somatic fiber involvement with relatively preserved autonomic innervation; and by contrast, PD+OH displays prevalent abnormal p‐syn deposits and denervation in autonomic postganglionic nerves. © 2020 International Parkinson and Movement Disorder Society


  • Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications

    by Aristide Merola, Alberto Romagnolo, Alok K. Dwivedi, Alessandro Padovani, Daniela Berg, Pedro J. Garcia-Ruiz, Margherita Fabbri, Carlo Alberto Artusi, Maurizio Zibetti, Leonardo Lopiano, et al.

    Objective We sought to evaluate demographic, clinical, and habits/occupational variables between phenotypic extremes in Parkinson’s disease (PD). Methods Databases from nine movement disorders centers across seven countries were retrospectively searched for subjects meeting criteria for very slowly progressive, benign, PD (bPD) and rapidly progressive, malignant, PD (mPD). bPD was defined as Hoehn and Yahr (H&Y) stage ≤ 3, normal cognitive function, and Schwab and England (S&E) score ≥ 70 after ≥ 20 years of PD (≥ 10 years if older than 60 at PD onset); mPD as H&Y > 3, S&E score < 70, and cognitive impairment within 10 years from PD onset. We performed between-group analysis of demographic, habits/occupational, and clinical features at baseline and follow-up and unsupervised data-driven analysis of the clinical homogeneity of bPD and mPD. Results At onset, bPD subjects (n = 210) were younger, had a single limb affected, lower severity and greater asymmetry of symptoms, and lower prevalence of depression than mPD (n = 155). bPD was associated with active smoking and physical activity, mPD with agricultural occupation. At follow-up, mPD showed higher prevalence of depression, hallucinations, dysautonomia, and REM behaviour disorder. Interestingly, the odds of mPD were significantly reduced by the presence of dyskinesia and wearing-off. Data-driven analysis confirmed the independent clustering of bPD and mPD, with age at onset emerging as a critical discriminant between the two groups (< 46-year-old vs. > 68-year-old). Conclusions Phenotypic PD extremes showed distinct demographic, clinical, and habits/occupational factors. Motor complications may be conceived as markers of therapeutic success given their attenuating effects on the odds of mPD.


  • Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy

    by Giacomo Monzio Compagnoni, Giulio Kleiner, Andreina Bordoni, Francesco Fortunato, Dario Ronchi, Sabrina Salani, Marianna Guida, Corrado Corti, Irene Pichler, Christian Bergamini, et al.